AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02673398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00962351 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Hip Replacement
Study NCT02877511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Applied liberally to the skin (Formulation: Y73-161
Study NCT02877511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen Lotion (Y65-110)
Description: Applied liberally to the skin
Study NCT04236193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Shoulder and Immunological Phenotyping by FACS
Description: Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements
Study NCT02234544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
Study NCT02234544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
Study NCT02234544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
Study NCT02234544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
Study NCT01741376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone 200 mg twice daily
Study NCT01741376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02560870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:Aloe Vera mouthwash
Description: mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
Study NCT01089608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Povidone
Description: Eye drops Single dose unit~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times.
Study NCT01585740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Crystalloid fluid
Study NCT01585740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Crystalloid fluid
Study NCT01470963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of referral template
Description: Implementation of referral template at the GP office
Study NCT03682861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 km time trial performance
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on time
Study NCT03682861 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 20 km time trial performance
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on time
Study NCT03682861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glycogen lowering exercise
Description: Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
Study NCT03682861 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Glycogen lowering exercise
Description: Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
Study NCT00832611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arteriovenous Fistula (ROX AC1)
Description: The percutaneous creation of an arteriovenous fistula.
Study NCT02931084 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: In line with current treatment guidelines, patients will undergo rehabilitation for at least the first three months, before a decision regarding ACL reconstruction is taken
Study NCT02560870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:Chlorhexidine mouthwash
Description: mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
Study NCT02931084 — intervention group
Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: Approximately half of the patients will have ACL-reconstruction after an initial time of rehabilitation
Study NCT03521115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Choices 4 Teens
Description: This is a web-based prevention program designed to convey information about alcohol and relationships and the types of choices that they are making regarding these topics. General communications was another core element of the program that provided parents and teens with some key elements of talking to each other.
Study NCT02968693 — intervention group
Intervention type: DEVICE
Intervention: antibiotic-loaded calcium sulfate
Description: To obtain a paste suitable for pellets, the following steps should be used: 1. Empty 10 cc Stimulan® calcium sulfate powder (Stimulan; Biocomposites Ltd; United Kingdom) into a sterile mixing bowl. 2. The calcium sulfate powder was mixed with 2,000 mg of vancomycin powder. 3. Add approximately 5 ml mixing solution into the above mixture. Mix thoroughly until a smooth paste is formed (approximately 30 seconds). 4. The resultant paste is uniformly smooth into the mould provided to form pellets with diameters of 4.8 mm and height of 3.3 mm. 5. Allow paste to cure undisturbed for at least 15 minutes after mixing. Flex mould to release pellets.
Study NCT02968693 — intervention group
Intervention type: DEVICE
Intervention: antibiotic-loaded polymethyl methacrylate
Description: One sachet of 40g PALACOSR®+G power containing 33.6g PMMA and with the addition of 0.5g gentamicin sulphate (Heraeus Medical Gesellschaft mit beschränkter Haftung,Germany) was mixed with 4,000 mg of vancomycin powder in a sterile bowl. The liquid provided was poured into the resultant mixture above. Then, the mixture was stirred carefully for 30 sec. If the dough-like mass no longer sticked to the rubber gloves, it can be progressed. If the required consistency was obtained, the cement can be applied to the bony defect until it hardened completely.
Study NCT02968693 — intervention group
Intervention type: DRUG
Intervention: Vancomycin
Description: Vancomycin powder was added into the combination therapy group and PMMA groups
Study NCT03672838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hand-held dynamometer
Description: Strength of one weak muscle group and of the biceps of the dominant arm will be measured using a hand-held dynamometer. An average of three readings will be used as one observation. Three observations per patient will be obtained on one day with a minimum of 15 minute rest period between each observation.
Study NCT01483729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Phase 3 Tablet Formulation 1, single oral dose
Study NCT01483729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Phase 3 Tablet Formulation 2, single oral dose
Study NCT04318184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise protocol was performed 3 times a week for 3 months on the treadmill. Loading periods were performed according to the heart rate maximum using the Karvonen formula (%60-80 Heart rate maximum)
Study NCT01483729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: Reference Phase 2 Tablet Formulation, single oral dose
Study NCT01483729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Reference Phase 2 Tablet Formulation, single oral dose
Study NCT03012464 — intervention group
Intervention type: OTHER
Intervention: Pathologic and functional assessment
Description: Random biopsies will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. Tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type I and type III, and to reveal any myopathic or degenerative changes
Study NCT01483729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Test Formulation 1, single oral dose
Study NCT01483729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Test Formulation 2, single oral dose
Study NCT01483729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: Reference Formulation, single oral dose
Study NCT01483729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Reference Formulation, single oral dose
Study NCT00434174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed.
Study NCT00434174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
Study NCT02880865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated SA 14-14-2 Japanese Encephalitis vaccine
Description: Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
Study NCT01060774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
Study NCT00448786 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 706
Description: Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
Study NCT00791206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real preconditioning
Description: Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
Study NCT02880865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, rubella vaccine
Description: Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
Study NCT00448786 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 706
Description: Arm C - 75 mg BID 5-days on, 2-days off
Study NCT00791206 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sham preconditioning
Description: Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
Study NCT01793961 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: electroretinogram
Study NCT01060774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
Study NCT00968383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta adrenergic blockers
Description: Participants will receive beta adrenergic blockers.
Study NCT00968383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta adrenergic blockers
Description: Participants will receive beta adrenergic blockers.
Study NCT00448786 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 706
Description: AMG 706 125 mg daily continuously (Arm A)
Study NCT02857309 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OPTIMIZER
Description: The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
Study NCT00968383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet inhibitors
Description: Participants will receive platelet inhibitors.
Study NCT01793961 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: contrast sensitivity tests
Study NCT02177526 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging
Description: 15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
Study NCT02401490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human albumin
Description: 1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
Study NCT00968383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet inhibitors
Description: Participants will receive platelet inhibitors.
Study NCT00968383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Participants will receive statins.
Study NCT00968383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins
Description: Participants will receive statins.
Study NCT00968383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitors and/or ARB and/or AA
Description: Participants will receive ACE inhibitors and/or ARB and/or AA
Study NCT00968383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitors and/or ARB and/or AA
Description: Participants will receive ACE inhibitors and/or ARB and/or AA
Study NCT00968383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI with stenting
Description: Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
Study NCT03867747 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac Radiosurgery
Description: Image-guided stereotactic body radiation therapy
Study NCT00071721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: 250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
Study NCT00071721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
Study NCT00791843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing hormone/ placebo
Description: 12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
Study NCT03645902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Study NCT02401490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04029701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruyizhenbao Pill
Description: Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
Study NCT02307383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactitol
Study NCT02307383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus
Study NCT04029701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Ruyizhenbao Pill
Description: Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
Study NCT01341002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: Red Blood Cells (RBC) Transfusion if SCVO2 \< 70% and guidelines
Study NCT01103037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAV680
Description: QAV680 500 mg (5 x 100 mg capsules) four times per day
Study NCT03048318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Flushing
Study NCT03048318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal Flushing
Study NCT03048318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal Flushing
Study NCT01263782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
Study NCT01103037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAV680 Placebo
Description: Placebo to QAV680 5 capsules four times per day
Study NCT01263782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 by vein on day 1 of each 21 day cycle.
Study NCT01341002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion
Description: transfusion based on guidelines
Study NCT01263782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg by vein on day 1 of each 21 day cycle.
Study NCT01263782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: 20 mg/kg by vein on day 1 of each 21 day cycle.
Study NCT02913274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) eluting angioplasty balloon
Description: Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation by a DEB of the same size for 2 minutes.
Study NCT02913274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-pressure angioplasty balloon
Description: Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.
Study NCT02913274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-pressure angioplasty balloon
Description: Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.
Study NCT02913274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-pressure balloon
Description: Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Thenn dilatation by a shame balloon i.e conventional low pression balloon of the same size for 2 minutes.
Study NCT02234830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoseal closure device
Description: Closure device for femoral artery access closure